» Articles » PMID: 7397941

A Sensitive Radioimmunoassay for Vincristine and Vinblastine

Overview
Specialty Oncology
Date 1980 Jan 1
PMID 7397941
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A rapid, sensitive and highly reproducible radioimmunoassay (RIA) has been devised for vincristine and vinblastine. These alkaloids bind to the antiserum very tightly with an association constant (Ka) of 5 x 10(9) M-1 as determined by Scatchard analysis. The kinetic association constant of the alkaloids, as determined by the 'on' and 'off' rates at 4 degrees C, is 30-fold higher than the Scatchard analysis value. At 4 degrees C, 80% of the alkaloid is bound to the antiserum within 20 min, and the remaining 20% reaches an equilibrium within 48-72 h. In the RIA procedure the amount of the alkaloid (1-2 ng) needed to compete for 50% binding remains unchanged when the reaction mixtures are incubated for 2, 4, or 20 h. By a modification of the RIA procedure, where the antiserum is first allowed to react with the unlabeled alkaloid followed by addition of the radiolabeled alkaloid, sensitivity of the assay has been increased five- to tenfold. Other drugs, such as adriamycin, CCNU, methyl CCNU, cyclophosphamide, 5-fluorouracil, heparin, hydrocortisone, prednisone, and nitrogen mustard do not interfere with the assay. This assay can thus be used to determine vincristine or vinblastine levels in 5 x 10(-10)--10(-9) M concentrations in biological fluids.

Citing Articles

Progress in Immunoassays of Toxic Alkaloids in Plant-Derived Medicines: A Review.

Ren Z, Zhang H, Wang Z, Chen X, Yang L, Jiang H Toxins (Basel). 2022; 14(3).

PMID: 35324662 PMC: 8948709. DOI: 10.3390/toxins14030165.


Pharmacokinetics of vincristine sulfate in children.

Sethi V, Kimball J Cancer Chemother Pharmacol. 1981; 6(2):111-5.

PMID: 7307229 DOI: 10.1007/BF00262326.


The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Steele W, King D, Barber H, Hawksworth G, Dawson A, Petrie J Eur J Clin Pharmacol. 1983; 24(5):683-7.

PMID: 6873152 DOI: 10.1007/BF00542223.


Continuous intravenous infusion of vinca alkaloid using a subcutaneously implanted pump in a canine model.

Jackson Jr D, Barringer M, Rosenbaum D, Long T, Sterchi J, Meredith W Cancer Chemother Pharmacol. 1983; 10(3):217-20.

PMID: 6861267 DOI: 10.1007/BF00255767.


Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine.

Young J, Howell S, Green M Cancer Chemother Pharmacol. 1984; 12(1):43-5.

PMID: 6690073 DOI: 10.1007/BF00255908.


References
1.
OWELLEN R, ROOT M, Hains F . Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 1977; 37(8 Pt 1):2603-7. View

2.
Jackson Jr D, Castle M, Bender R . Biliary excretion of vincristine. Clin Pharmacol Ther. 1978; 24(1):101-7. DOI: 10.1002/cpt1978241101. View

3.
Bender R, Castle M, Margileth D, OLIVERIO V . The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther. 1977; 22(4):430-5. DOI: 10.1002/cpt1977224430. View

4.
Castle M, Margileth D, OLIVERIO V . Distribution and excretion of (3H)vincristine in the rat and the dog. Cancer Res. 1976; 36(10):3684-9. View

5.
OWELLEN R, Hartke C . The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. Cancer Res. 1975; 35(4):975-80. View